Article info
PDFColon
Original article
Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial
- Correspondence to Professor Robin C Spiller, Nottingham Digestive Diseases Centre, University of Nottingham, Queens Medical Centre, Nottingham NG7 2UH, UK; robin.spiller{at}nottingham.ac.uk
Citation
Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial
Publication history
- Received May 12, 2018
- Revised August 28, 2018
- Accepted August 29, 2018
- First published September 25, 2018.
Online issue publication
August 21, 2019
Article Versions
- Previous version (8 August 2019).
- Previous version (8 August 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.